Today in Biology — Aug 7

[SOFIA] Welcome back to The Dish! Today in Biology, we're zooming in on some big shifts in national science funding and initiatives, especially how they're pushing the envelope for engineering biology. And let's be honest, where the money goes often dictates what gets built, right?

[DANIEL] Indeed. Following the money trail reveals a lot about the strategic priorities. And sometimes, it reveals where the priorities might be shifting away from, too.

[SOFIA] Exactly. So, let's dive straight in. The biggest news this week, and honestly, this is the good stuff for anyone thinking about large-scale, AI-driven biology: The Department of Energy has just committed *five billion dollars* to its Genesis Mission. Five billion, Daniel. They've selected 278 projects, and while nuclear research got a huge slice, a significant part of this is about applying AI to a massive range of scientific and technological challenges, including, I'd imagine, a lot of biology.

[DANIEL] That's a substantial investment. The DOE's involvement in biology, particularly with their national labs, often means tackling problems at a scale few other agencies can. We're talking about industrial-level bioprocessing, environmental remediation, and bioenergy. The integration of AI into these projects isn't just about faster data analysis; it's about optimizing complex biological systems, predicting outcomes in metabolic pathways, or even designing novel enzymes with unprecedented efficiency.

[SOFIA] And we're already seeing some concrete examples. Savannah River National Laboratory, for instance, just got awards for AI-powered cleanup projects through Genesis. So it’s not just theoretical; it's about real-world, large-scale problems like environmental remediation, which often involves engineering microbes to degrade pollutants. For people in our field, this means a massive new push for AI tools to design and optimize biological systems for very specific, often harsh, environmental conditions.

[DANIEL] What's crucial to watch with these large-scale AI initiatives is how they define "AI-powered." Is it simply machine learning applied to existing data sets, or is it genuinely driving novel experimental design and discovery cycles? The success will hinge on whether these AI models can generate experimentally verifiable hypotheses, rather than just post-hoc explanations.

[SOFIA] Totally. We need to see that loop closing. Now, on a slightly different note, ARPA-H, which is still quite new, is also making moves that directly impact engineering biology. DNA Script, which we’ve talked about before for their enzymatic DNA synthesis, just got awarded up to 26 million dollars to advance cell-free DNA bioproduction.

[DANIEL] This is interesting because ARPA-H's mandate is to fund high-risk, high-reward projects that could lead to transformative health outcomes. Cell-free DNA bioproduction, that is, synthesizing DNA without needing living cells, offers incredible advantages in speed, purity, and scalability. If they can truly scale this for therapeutic or diagnostic applications, it dramatically streamlines the development of things like mRNA vaccines or gene therapies, which rely on having a lot of very specific DNA templates.

[SOFIA] Right? Think about it — no need to transform bacteria with plasmids, grow them up, extract the DNA. Just enzymes in a tube. That removes a huge bottleneck for a lot of engineering biology applications, especially for those non-model organisms that are notoriously hard to transform. It’s about making the fundamental building blocks of genetic engineering much more accessible and faster to produce.

[DANIEL] The precision and error rates for these enzymatic synthesis methods will be paramount, particularly at scale. And the cost-effectiveness, of course. It’s one thing to synthesize a gene; it’s another to produce kilograms of therapeutic-grade DNA.

[SOFIA] Absolutely. And just quickly, before we wrap up, we're seeing some shifts at the NIH. There’s been some discussion online about NIH Director Bhattacharya, with arguments circulating that more health disparities grants are being terminated. This could signal a re-evaluation of funding priorities or a shift in how those initiatives are structured.

[DANIEL] Any re-prioritization at the NIH, especially concerning grant terminations, warrants close attention. It can create significant instability for researchers in specific fields and potentially shift the landscape of what research questions are being pursued and by whom. The specifics of *why* these grants are being terminated, whether it's a strategic shift or a performance-based decision, are crucial to understanding the broader impact.

[SOFIA] And finally, a shout-out to the NSF, which just awarded the University of Maryland $17.3 million for a test bed for automated biomanufacturing workflows. This is all about programming robots to do biology, which is essential for scaling up any engineering biology project. It's building the infrastructure for the future.

[DANIEL] An automated test bed like that is critical for reproducibility and for high-throughput exploration of design space in synthetic biology. It removes human variability and allows for truly systematic optimization.

[SOFIA] All right, we've covered a lot of ground today on Today in Biology. From billions for AI in science to new ways of making DNA and automated labs, it's clear the landscape for engineering biology is rapidly evolving. We'll be keeping a close eye on all of it. Thanks for joining us on The Dish.